慢性関節リウマチ  [in Japanese] Rheumatoid arthritis.:Rheumatoid arthritis  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

Rheumatoid arthritis is a chronic inflammatory disease of joints with the potential to cause substantial joint damage and disability. Proinflammatory cytokines(TNF<I>α</I>, IL-6, IL-1) have recently been shown to play important roles in the pathogenesis of rheumatoid arthritis. In addition, advances in the field of genetic engineering have made possible therapies using monoclonal antibody targeting specific inflammatory mediators. Infliximab is a chimeric anti-TNF<I>α</I> monoclonal antibody that is already available for rheumatoid arthritis patients in the United States and European countries following the results of multiple double-blinded placebo-controlled trials. Infliximab has been demonstrated to improve symptoms and signs of synovitis, and to prevent radiographic evidence of progeressive joint damage in a majority of patients with rheumatoid arthritis. However, increased susceptibility to infection is a potential concern with agents inhibiting TNF<I>α</I> as the cytokine plays a central role in host defense. In fact, several kinds of infection, including tuberculosis, have been reported as adverse events following anti-TNF<I>α</I> blockade therapy. Physicians are therefore recommended to screen patients for latent tuberculosis infection or disease before initiating such therapies. IL-6 is likely to be involved in the pathogenesis of rheumatoid arthritis in addition to TNF<I>α</I>. Clinical trials into IL-6 blockade therapy using complementarity determining regions (CDR)-grafted anti-human IL-6 receptor monoclonal antibody have therefore started. In the near future, these anti-cytokine therapies will become part of the standard armamentarium for the treatment of rheumatoid arthritis in Japan.

Journal

  • Drug Delivery System

    Drug Delivery System 17(1), 50-57, 2002-01-10

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References:  24

Cited by:  1

Codes

  • NII Article ID (NAID)
    10008132059
  • NII NACSIS-CAT ID (NCID)
    AN10084591
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    09135006
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top